Balaji Prasad
Stock Analyst at Barclays
(2.42)
# 2,428
Out of 4,931 analysts
132
Total ratings
42.74%
Success rate
-0.25%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $6.07 | +311.86% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $8.21 | +33.98% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $23.77 | +0.97% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $9.39 | -4.15% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $112.08 | +78.44% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $16.48 | +15.29% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $47.95 | +25.13% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $148.24 | +64.60% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.11 | +163.45% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $27.28 | -19.35% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $650.06 | -20.01% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $16.29 | +59.61% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.60 | +25.00% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.46 | +112.89% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.21 | +211.53% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.88 | +691.94% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $6.07
Upside: +311.86%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $8.21
Upside: +33.98%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $23.77
Upside: +0.97%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $9.39
Upside: -4.15%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $112.08
Upside: +78.44%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $16.48
Upside: +15.29%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $47.95
Upside: +25.13%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $148.24
Upside: +64.60%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.11
Upside: +163.45%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $27.28
Upside: -19.35%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $650.06
Upside: -20.01%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.29
Upside: +59.61%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.60
Upside: +25.00%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.46
Upside: +112.89%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.21
Upside: +211.53%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.88
Upside: +691.94%